Experimental drug

Phase 3Small molecule

MMedesis Pharma SA

Experimental drug is one of 92 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CancerActive, not recruiting

ChemotherapyNot yet recruiting

SintilimabRecruiting

Acne VulgarisNot yet recruiting

Pancreatic CancerPreclinical

Active, not recruiting

ChemotherapyPhase 2

Not yet recruiting

SintilimabPhase 3

Recruiting

Acne VulgarisPhase 3

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Experimental drug

MMedesis Pharma SA

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Sintilimab

NCT05768503

Phase 3Not yet recruiting

Acne Vulgaris

NCT06905210

Q4 2027

Phase 2Not yet recruiting

Chemotherapy

NCT06752382

Clinical

Trials by Indication[1]

COVID-192 trials

IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.

Unknown status·VVersailles Hospital·Phase 2·NCT04357613·99 enrolled

NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

Terminated·MMedesis Pharma SA·Phase 1/2·NCT05451654·7 enrolled

Acne Vulgaris1 trial

Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris

Not yet recruiting·EEurofarma Laboratorios S.A.·Phase 3·NCT06905210·526 enrolled

Clinical Trial1 trial

Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment

Completed·EEurofarma Laboratorios S.A.·Phase 3·NCT05118672·567 enrolled

Pregabalin1 trial

Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

Completed· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 1·NCT02103686·30 enrolled

Chemotherapy1 trial

Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC

Not yet recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT06752382·58 enrolled

4 more indications

Sintilimab1 trial

Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

Recruiting·SSun Yat-sen University·Phase 3·NCT05768503·176 enrolled

Colorectal Cancer1 trial

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05409417·40 enrolled

Pancreatic Cancer1 trial

Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

Completed·VVejle Hospital··NCT03821870·12 enrolled

Fecal Microbiota Transplantation1 trial

FEcal Microbiota Transplantation

Unknown status·AAssistance Publique Hopitaux De Marseille·N/A·NCT04001439·3,088 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Experimental drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Experimental drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Experimental drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medesis Pharma SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedesis Pharma SA

Experimental drug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

COVID-192 trials

Acne Vulgaris1 trial

Clinical Trial1 trial

Pregabalin1 trial

Chemotherapy1 trial

Sintilimab1 trial

Colorectal Cancer1 trial

Pancreatic Cancer1 trial

Fecal Microbiota Transplantation1 trial

References

Drug Info

Quick Facts

Related News